丙型肝炎药物市场按药物类别、给药途径、分销管道和地区划分

预计 2025 年全球丙型肝炎药物市场规模为 98.6 亿美元，到 2032 年将达到 132.4 亿美元，2025 年至 2032 年的复合年增长率为 4.3%。

数字。 2025年C型肝炎药物市场占有率（按地区）

丙型肝炎是一种肝臟感染疾病，可导致严重的肝损伤。它是由C型肝炎病毒引起的。美国约有240万人受到影响。然而，大多数丙型肝炎患者不会出现任何症状，因为该病毒很少引起症状。病毒透过感染者的血液和体液传播。

丙型肝炎分期潜伏期。这是从初次接触到发病之间的时间段。潜伏期14～80天，平均45天。急性C型肝炎：这是病毒进入人体后持续六个月的短期疾病。有些人随后能够自行摆脱病毒。慢性C型肝炎大多数C型肝炎患者（高达 85%）会发展为长期疾病阶段（持续时间超过 6 个月）。这被称为慢性丙型肝炎感染，可导致肝癌和肝硬化等严重的健康问题。肝硬化。这种疾病会引起炎症，随着时间的推移，健康的肝细胞会被疤痕组织所取代。饮酒或感染爱滋病毒会更快导致肝硬化，但肝臟通常需要约20至30年的时间才会发展为肝硬化。

市场动态：

预计预测期内全球丙型肝炎盛行率的上升将推动市场成长。例如，根据美国国家生物技术资讯中心2021年9月18日发布的数据，印度丙型肝炎病毒的盛行率为0.5%，约有470万至1,090万人受到影响。

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章市场动态、法规与趋势分析

• 市场动态
  • 驱动程式
• 全球丙型肝炎疫情呈上升趋势
• 加强政府努力
  • 限制因素
• 副作用增加
  • 机会
• 提高不同地区的产品供应量
• 影响分析
• 主要亮点
• 监管情景
• 产品发布/核准
• PEST分析
• 波特分析
• 併购场景

第四章丙型肝炎药物市场-冠状病毒 (COVID-19) 大流行的影响

• COVID-19流行病学
• 供需侧分析
• 经济影响

5. 丙型肝炎药物市场（依药物类别划分），2020 年至 2032 年

• NS3/4A蛋白酶抑制剂
• NS5A抑制剂
• NS5B聚合酵素抑制剂
• 伴随用药
• 其他的

6. 2020 年至 2032 年按给药途径分類的C型肝炎药物市场

• 口服药物
• 静脉
• 其他的

7. 丙型肝炎药物市场（依分销管道划分），2020 年至 2032 年

• 医院药房
• 零售药局
• 网路药局

8. 2020 年至 2032 年C型肝炎药物市场（依地区划分）

• 北美洲
• 欧洲
• 亚太地区
• 拉丁美洲
• 中东
• 非洲

第九章 竞争态势

• Gilead Sciences
• AbbVie
• Merck & Co
• Bristol-Myers Squibb
• Johnson & Johnson
• Hoffmann-La Roche AG
• Boehringer Ingelheim
• Achillion Pharmaceuticals

第 10 章 章节

• 调查方法
• 关于出版商

Global Hepatitis C Drugs Market is estimated to be valued at USD 9.86 Bn in 2025 and is expected to reach USD 13.24 Bn by 2032, growing at a compound annual growth rate (CAGR) of 4.3% from 2025 to 2032.

Figure. Hepatitis C Drugs Market Share (%), By Region 2025

Hepatitis C is a liver infection that can lead to serious liver damage. It's caused by the hepatitis C virus. About 2.4 million people in the U.S. have the disease. But it causes few symptoms, so most of them don't know. The virus spreads through an infected person's blood or body fluids.

Stages of Hepatitis C: Incubation period. This is the time between first exposures to the start of the disease. It can last anywhere from 14 to 80 days, but the average is 45. Acute hepatitis C. This is a short-term illness that lasts for the first 6 months after the virus enters your body. After that, some people who have it will get rid of, or clear, the virus on their own. Chronic hepatitis C. For most people who get hepatitis C - up to 85% - the illness moves into a long-lasting stage (longer than 6 months). This is called a chronic hepatitis C infection and can lead to serious health problems like liver cancer or cirrhosis. Cirrhosis. This disease leads to inflammation that, over time, replaces your healthy liver cells with scar tissue. It usually takes about 20 to 30 years for this to happen, though it can be faster if you drink alcohol or have HIV.

Market Dynamics:

The increasing prevalence of hepatitis C globally is expected to aid in the market growth over the forecast period. For instance, according to the data published by the National Center for Biotechnology Information on September 18, 2021, the prevalence rate of HCV in India is 0.5%, affecting about 4.7 to 10.9 million people.

Hepatitis C Drugs Market Segmentation:

• By Drug Class
  • NS3/4A Protease Inhibitors
  • NS5A Inhibitors
  • NS5B Polymerase Inhibitors
  • Combination Drugs
  • Others
• By Route of Administration
  • Oral Drugs
  • Intravenous
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Company Profiles
  • Gilead Sciences
  • AbbVie
  • Merck & Co
  • Bristol-Myers Squibb
  • Johnson & Johnson
  • Hoffmann-La Roche AG
  • Boehringer Ingelheim
  • Achillion Pharmaceuticals

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Route of Administration
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
• Growing Prevalence of Hepatitis C Globally
• Increasing Government Initiatives
  • Restraints
• Increasing Adverse Effects
  • Opportunities
• Increasing Product Availability in Various Regions
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Hepatitis C Drugs Market- Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Hepatitis C Drugs Market, By Drug Class, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• NS3/4A Protease Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• NS5A Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• NS5B Polymerase Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Combination Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

6. Hepatitis C Drugs Market, By Route of Administration, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• Oral Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
• Intravenous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)

7. Hepatitis C Drugs Market, By Distribution Channel, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)

8. Hepatitis C Drugs Market, By Region, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, By Country, 2025and 2032 (%)
  • Y-o-Y Growth Analysis, For Country 2021-2032
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • China
    • Japan
    • India
    • Australia
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• Gilead Sciences
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AbbVie
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Merck & Co
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Johnson & Johnson
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Hoffmann-La Roche AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Boehringer Ingelheim
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Achillion Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Analyst Views

10. Section

• Research Methodology
• About us